OS Therapies (OSTX) Competitors $2.26 -0.24 (-9.60%) Closing price 04:00 PM EasternExtended Trading$2.25 -0.01 (-0.44%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. CTNM, VOR, DBVT, MREO, JBIO, LXEO, PBYI, ALLO, TVRD, and GALTShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Contineum Therapeutics (CTNM), Vor Biopharma (VOR), DBV Technologies (DBVT), Mereo BioPharma Group (MREO), Jade Biosciences (JBIO), Lexeo Therapeutics (LXEO), Puma Biotechnology (PBYI), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Its Competitors Contineum Therapeutics Vor Biopharma DBV Technologies Mereo BioPharma Group Jade Biosciences Lexeo Therapeutics Puma Biotechnology Allogene Therapeutics Tvardi Therapeutics Galectin Therapeutics Contineum Therapeutics (NASDAQ:CTNM) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Is CTNM or OSTX more profitable? OS Therapies' return on equity of 0.00% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -29.75% -28.08% OS Therapies N/A N/A -569.57% Does the media favor CTNM or OSTX? In the previous week, OS Therapies had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for OS Therapies and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.90 beat OS Therapies' score of 0.39 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OS Therapies 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CTNM or OSTX? Contineum Therapeutics currently has a consensus target price of $22.75, indicating a potential upside of 126.37%. OS Therapies has a consensus target price of $18.00, indicating a potential upside of 696.46%. Given OS Therapies' stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher earnings and valuation, CTNM or OSTX? OS Therapies has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than OS Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M5.64-$42.26M-$2.20-4.57OS TherapiesN/AN/A-$7.79M-$0.79-2.86 SummaryOS Therapies beats Contineum Therapeutics on 6 of the 10 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$72.08M$848.51M$5.78B$21.32BDividend YieldN/A4.84%3.95%3.51%P/E Ratio-2.861.1122.5626.70Price / SalesN/A26.55463.8452.86Price / CashN/A19.5637.7323.86Price / BookN/A6.7310.045.39Net Income-$7.79M-$4.20M$3.27B$996.59M7 Day Performance-5.83%15.34%3.17%3.12%1 Month Performance25.56%16.63%4.34%2.97%1 Year Performance-37.91%33.32%44.12%12.83% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.3717 of 5 stars$2.26-9.6%$18.00+696.5%-38.1%$72.08MN/A-2.86N/ANews CoverageAnalyst ForecastCTNMContineum Therapeutics3.3128 of 5 stars$10.39+4.5%$22.75+119.0%-49.6%$278.74M$50M-4.7231VORVor Biopharma0.296 of 5 stars$2.06-5.1%N/AN/A$274.90MN/A-0.15140News CoveragePositive NewsGap UpDBVTDBV Technologies3.3996 of 5 stars$9.79-2.1%$14.75+50.7%+111.9%$273.90M$4.15M-2.0580MREOMereo BioPharma Group1.8886 of 5 stars$1.74+2.4%$7.40+325.3%-63.3%$270.30M$10M-24.8640News CoverageAnalyst ForecastJBIOJade Biosciences2.1653 of 5 stars$7.90-4.0%$16.00+102.5%N/A$268.52MN/A-0.2620LXEOLexeo Therapeutics2.5534 of 5 stars$4.66-4.9%$15.33+229.0%-56.1%$264.61M$650K-1.4358News CoveragePBYIPuma Biotechnology4.1082 of 5 stars$4.99-5.0%$7.00+40.3%+100.8%$264.45M$230.50M5.09200Positive NewsALLOAllogene Therapeutics2.8639 of 5 stars$1.16-2.5%$8.44+628.0%-56.7%$264.04M$20K-1.05310TVRDTvardi Therapeutics1.5891 of 5 stars$29.20+4.1%$64.25+120.0%N/A$263.04MN/A0.0080Gap DownGALTGalectin Therapeutics2.4091 of 5 stars$4.00-2.4%$6.00+50.0%+51.9%$262.65MN/A-6.259 Related Companies and Tools Related Companies Contineum Therapeutics Competitors Vor Biopharma Competitors DBV Technologies Competitors Mereo BioPharma Group Competitors Jade Biosciences Competitors Lexeo Therapeutics Competitors Puma Biotechnology Competitors Allogene Therapeutics Competitors Tvardi Therapeutics Competitors Galectin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access